僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Emibetuzumab （LY2875358） is a humanized bivalent MET antibody （IgG4 type）. Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer